1291 / 1694
62
patients with
pT2-T4a N0 M0
bladder
carcinoma unsuitable for standard daily
radiotherapy
Group 1:
STANDARD PLANNING
(CONTROL)
Group 2:
ADAPTIVE PLANNING
(EXPERIMENTAL)
RANDOMISE
1:1
Follow up
•
Weekly on treatment
•
4 weeks after last treatment
•
3 months after last treatment
•
6, 12 and 24 months
Due to receive six 6Gy fractions of
radiotherapy delivered weekly
(total dose: 36Gy over 6 weeks)
in partnership with
National Trial